Replies to post #108154 on Cytodyn Inc (CYDY)

[AaHh]

That’s why I’m afraid our S/C trial may be unsuccessuful, unless they can change the primary endpoint, which endpoint (mortality) even NP said is very difficult to achieve. I’m not any expert but I think we’ll have better success with the M/M phase 3.

[Blane]

Especially if you count for Leronlimab’s data as a stand alone treatment. Lack of sides, improved cytokine numbers, clinical improvement, cost savings on not using as many other drugs, decrease in drugs to drug actions, decrease stay in hospital, decrease in upgrade in care, decrease in long term side effects from Covid, boosting immune system to help with antibody production,... Yada yada

It’s a no brainer imo.